PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-1.74%
Negative net income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect a firm-specific problem if peers maintain profit growth.
-1.18%
D&A shrinks yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a short-term earnings benefit if capacity is sufficient.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.51%
Working capital is shrinking yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see an advantage if sales remain robust.
No Data
No Data available this quarter, please select a different quarter.
778.85%
Inventory growth of 778.85% while Medical - Pharmaceuticals median is zero at 0.00%. Walter Schloss would question if expansions or new product lines require extra stock.
No Data
No Data available this quarter, please select a different quarter.
-42.42%
Other WC usage shrinks yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see an advantage if top-line is stable or growing.
-565.92%
Other non-cash items dropping yoy while Medical - Pharmaceuticals median is -7.75%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
-52.95%
Negative CFO growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
-61.94%
CapEx declines yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
58.50%
Growth of 58.50% while Medical - Pharmaceuticals median is zero at 0.00%. Walter Schloss questions intangible or special projects explaining that difference.
-31.81%
Reduced investing yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
1.40%
Debt repayment growth of 1.40% while Medical - Pharmaceuticals median is zero at 0.00%. Walter Schloss wonders if expansions or a shift in capital structure drive that difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.